Expertise in
2
conditions

Dr. Muhammad Irfan

Internal Medicine
Kingman Regional Medical Center
3269 N Stockton Hill Rd, 
Kingman, AZ 
Expertise in
2
conditions
Kingman Regional Medical Center
3269 N Stockton Hill Rd, 
Kingman, AZ 

Overview

Muhammad Irfan is a primary care provider, practicing in Internal Medicine in Kingman, Arizona.

Dr. Irfan is highly rated in 2 conditions, according to our data. His clinical expertise encompasses Familial Hemiplegic Migraine, Migraine with Brainstem Aura, Ulcerative Colitis, and Hemorrhagic Proctocolitis.

He is actively involved in clinical research, co-authoring 2 peer reviewed articles and participating in 10 clinical trials.

Specialties

Internal Medicine

Hospital Affiliations

Kingman Regional Medical Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alliant Health
  • HMO
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

Kingman Regional Medical Center
3269 N Stockton Hill Rd, Kingman, AZ 86409
Other Locations
Wellstar Spalding Regional Hospital
601 S 8th St, Griffin, GA 30224

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)
Enrollment Status: Completed
Publish Date: May 13, 2026
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
Enrollment Status: Completed
Publish Date: May 31, 2025
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3 Safety, Immunogenicity, and Lot-Consistency Trial of the VLP-Based Chikungunya Vaccine PXVX0317 in Healthy Adults and Adolescents
A Phase 3 Safety, Immunogenicity, and Lot-Consistency Trial of the VLP-Based Chikungunya Vaccine PXVX0317 in Healthy Adults and Adolescents
Enrollment Status: Completed
Publish Date: August 30, 2024
Intervention Type: Biological
Study Phase: Phase 3
A Phase 4, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Galcanezumab Versus Rimegepant in Adult Participants With Episodic Migraine
A Phase 4, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Galcanezumab Versus Rimegepant in Adult Participants With Episodic Migraine
Enrollment Status: Completed
Publish Date: June 28, 2024
Intervention Type: Drug
Study Drugs: Galcanezumab, Rimegepant
Study Phase: Phase 4
A Phase 3 Long-term Safety Extension Study of SHP647 in Subjects With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)
A Phase 3 Long-term Safety Extension Study of SHP647 in Subjects With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)
Enrollment Status: Completed
Publish Date: June 21, 2024
Intervention Type: Drug
Study Drug: Ontamalimab
Study Phase: Phase 3
A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
Enrollment Status: Completed
Publish Date: November 27, 2023
Intervention Type: Drug
Study Drug: Dihydroergotamine
Study Phase: Phase 3
An Open-Label, 12-Month Study to Evaluate the Safety and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
An Open-Label, 12-Month Study to Evaluate the Safety and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
Enrollment Status: Completed
Publish Date: July 03, 2023
Intervention Type: Drug
Study Drug: Dihydroergotamine
Study Phase: Phase 3
EMERGE: A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Single Doses of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
EMERGE: A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Single Doses of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
Enrollment Status: Completed
Publish Date: June 29, 2023
Intervention Type: Drug
Study Phase: Phase 3
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 303)
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 303)
Enrollment Status: Completed
Publish Date: January 14, 2022
Intervention Type: Other, Drug
Study Phase: Phase 3
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 301)
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 301)
Enrollment Status: Terminated
Publish Date: June 14, 2021
Intervention Type: Other, Drug
Study Phase: Phase 3
View 9 Less Clinical Trials

2 Total Publications

Phase 1/2 randomized, observer-blind clinical trial of a first-generation, mRNA-based vaccine against seasonal influenza and COVID-19 in healthy adults.
Phase 1/2 randomized, observer-blind clinical trial of a first-generation, mRNA-based vaccine against seasonal influenza and COVID-19 in healthy adults.
Journal: Human vaccines & immunotherapeutics
Published: February 02, 2026
Similar Doctors
Expertise in
15
conditions
Dr. Sungnam Joe
Internal Medicine
Expertise in
15
conditions
Dr. Sungnam Joe
Internal Medicine

Kingman Regional Medical Center

2226 Hualapai Mountain Rd Ste 101, 
Kingman, AZ 
 (2.0 miles away)
928-681-8530
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Sungnam Joe is a primary care provider, practicing in Internal Medicine in Kingman, Arizona. Dr. Joe is highly rated in 15 conditions, according to our data. His clinical expertise encompasses Hypothyroidism, Familial Combined Hyperlipidemia, Xanthoma, and Cirrhosis. Dr. Joe is currently accepting new patients.

Expertise in
38
conditions
Dr. Maria Salamatin
Internal Medicine
Expertise in
38
conditions
Dr. Maria Salamatin
Internal Medicine

Desert Angels Medical Clinic PLC.

3003 Highway 95 Ste 101, 
Bullhead City, AZ 
 (30.9 miles away)
928-758-0202
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Maria Salamatin is a primary care provider, practicing in Internal Medicine in Bullhead City, Arizona. Dr. Salamatin is highly rated in 38 conditions, according to our data. Her clinical expertise encompasses Familial Combined Hyperlipidemia, Xanthoma, Cirrhosis, and High Cholesterol.

Expertise in
72
conditions
Dr. Raghav Mohindra
Internal Medicine
Expertise in
72
conditions
Dr. Raghav Mohindra
Internal Medicine

Lake Havasu City

1972 Mesquite Ave, 
Lake Havasu City, AZ 
 (54.0 miles away)
928-493-9937
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Raghav Mohindra is a primary care provider, practicing in Internal Medicine in Lake Havasu City, Arizona. Dr. Mohindra is highly rated in 72 conditions, according to our data. His clinical expertise encompasses Multiple System Atrophy, Vertigo, Subacute Combined Degeneration, and Glucocorticoid-Remediable Aldosteronism.

Frequently Asked Questions about Dr. Muhammad Irfan

How do I make an appointment with Dr. Muhammad Irfan?

You can book an appointment with Dr. Muhammad Irfan by calling their office at 928-681-8577. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Muhammad Irfan a top-rated expert for Familial Hemiplegic Migraine?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Muhammad Irfan is classified as an Advanced expert for Familial Hemiplegic Migraine, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Muhammad Irfan specialize in?

While Dr. Muhammad Irfan is a Internal Medicine, they have specific expertise in Familial Hemiplegic Migraine, Migraine with Brainstem Aura, and Ulcerative Colitis. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Internal Medicine.

Does Dr. Muhammad Irfan participate in research or clinical trials?

Yes. Dr. Muhammad Irfan has published 2 articles and abstracts on conditions like Familial Hemiplegic Migraine. You can view a list of Dr. Muhammad Irfan's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Muhammad Irfan accept my insurance?

Dr. Muhammad Irfan accepts most major insurance plans, including Aetna and Alliant Health. We recommend calling the office directly at 928-681-8577 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Irfan's expertise for a condition
ConditionClose
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile